Top Markets
Coin of the day
Dong-A ST Co., Ltd. Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd.

170900
Rank in Stocks #17344
Dong-A ST Co., Ltd. is a global enterprise focused on the research,... Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
Share Price
$25.52
Market Cap
$246.07M
Change (1 day)
-2.25%
Change (1 year)
-4.13%
Country
KR
Trade Dong-A ST Co., Ltd. (170900)

Category

P/B ratio for Dong-A ST Co., Ltd. (170900)
P/B ratio as of 2026 TTM: 0
According to Dong-A ST Co., Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Dong-A ST Co., Ltd. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors